依那西普和传统合成改变病情抗风湿药序贯治疗轻中度强直性脊柱炎的中期疗效随访研究

doi:10.13418/j.issn.1001-165x.2023.1.18

中国临床解剖学杂志 ›› 2023, Vol. 41 ›› Issue (1): 97-104.doi: 10.13418/j.issn.1001-165x.2023.1.18

依那西普和传统合成改变病情抗风湿药序贯治疗轻中度强直性脊柱炎的中期疗效随访研究

江伟州¹，胡勇²，宋旻恺¹，刘欢³，黄文华⁴，肖军¹*

1.南方医科大学附属南方医院关节与骨病外科，广州 510515； 2.南方医科大学第五附属医院关节外科，广州 510999； 3.西南医科大学附属中医医院骨伤科，四川泸州 646000； 4.南方医科大学基础医学院人体解剖学教研室，广州 510515

收稿日期:2021-07-19 出版日期:2023-01-25 发布日期:2023-02-08
通讯作者: 肖军，副主任医师，副教授，硕士研究生导师，E-mail：orthopaedxj@163.com
作者简介:江伟州（1993-），男，广东普宁人，住院医师，博士研究生，E-mail：orthopaedjoe@163.com
基金资助:
广东省教育厅高水平大学建设经费南方医科大学临床研究启动项目（LC2019ZD022）；南方医科大学南方医院临床研究专项（2018CR001,2020CR028）

Sequential application of etanercept and csDMARDs in treating ankylosing spondylitis: A prospectively mid-term follow-up study

Jiang Weizhou¹, Hu Yong², Song Minkai¹, Liu Huan³, Huang Wenhua⁴, Xiao Jun¹*

1. Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2.Department of Joint Surgery, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou 510999, China; 3.Department of Orthopaedics, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China; 4. Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China

Received:2021-07-19 Online:2023-01-25 Published:2023-02-08

摘要/Abstract

摘要： 目的随访评估依那西普和传统合成改变病情抗风湿药（conventional synthetic disease modifying anti-rheumatic drugs，csDMARDs）序贯治疗强直性脊柱炎（ankylosing spondylitis，AS）的药物组合方案治疗轻中度AS的中期疗效。方法纳入南方医院2017~2018年确诊的轻中度AS患者64例，疾病活动期短期选用依那西普，疾病缓解期改用csDMARDs药物组合口服维持。分别于治疗前，治疗后3、6、12个月评估临床缓解率，并应用BASFI、BASDAI、SQOL-AS量表评价治疗效果。结果随访3、6、12个月，Patient Global、BASFI、BASDAI及ASDAS-CRP评分，CRP及ESR值均下降（P<0.05），SQOL-AS评分提高（P<0.05）。随访终点分别有85.9%、79.7%的患者达到ASAS 20、ASAS 40缓解标准。随访期间无结核、机会感染、肿瘤发生。结论对于轻中度AS，依那西普和csDMARDs序贯组合方案展示了良好的中期疗效，有望成为低收入AS患者的替代治疗方案。

关键词: 强直性脊柱炎； , , 传统合成改变病情抗风湿药； , , 临床方案

Abstract: Objective To evaluate etanercept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) in treating ankylosing spondylitis (AS) and its mid-term therapeutic effect among mild-to-moderate AS patients. Methods Sixty-four patients diagnosed with mild-to-moderate AS treating in our department from 2017 to 2018 were enrolled. Etanercept was used in the short term during the active stage of the disease, and csDMARDs combination was used for oral administration during the remission stage. Clinical remission rate was assessed before treatment, 3, 6 and 12 months after treatment. Tthe therapeutic effect was evaluated by BASFI, BASDAI and SQOL-AS scales. Results Patients Global, BASFI, BASDAI and ASDAS-CRP scores, CRP and ESR values decreased (P<0.05), while SQOL-AS scores increased (P<0.05) at 3, 6 and 12 months of follow-up. At the end of the follow-up, 85.9% and 79.7% of all enrolled patients achieved ASAS 20, ASAS 40 remission criteria, respectively. No tuberculosis, opportunistic infection or tumor occurred during the treatment. Conclusions For mild to moderate AS, the sequential combination of etanercept and csDMARDs shows satisfied mid-term therapeutic efficacy and expects to be an alternative treatment for those low-income AS patients.

Key words: Ankylosing spondylitis (AS); , Conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs); , , Therapy

中图分类号:

R681.51

江伟州, 胡勇, 宋旻恺, 刘欢, 黄文华, 肖军. 依那西普和传统合成改变病情抗风湿药序贯治疗轻中度强直性脊柱炎的中期疗效随访研究[J]. 中国临床解剖学杂志, 2023, 41(1): 97-104.

Jiang Weizhou, Hu Yong, Song Minkai, Liu Huan, Huang Wenhua, Xiao Jun. Sequential application of etanercept and csDMARDs in treating ankylosing spondylitis: A prospectively mid-term follow-up study[J]. Chinese Journal of Clinical Anatomy, 2023, 41(1): 97-104.

参考文献 15

[1]	Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis[J]. Cochrane Database Syst Rev, 2015(4): Cd005468. DOI: 10.1002/14651858.CD005468.pub2.
[2]	Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis[J]. Arthritis Care Res (Hoboken), 2019, 71(10): 1285-1299. DOI: 10.1002/acr.24025.
[3]	Tam LS, Wei JC. 2018 APLAR axial spondyloarthritis treatment recommendations[J]. Int J Rheum Dis, 2019, 22(3): 340-356. DOI: 10.1111/1756-185X.13510.
[4]	Chan J, Gladman D. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors[J]. Best Pract Res Clin Rheumatol, 2018, 32(3): 415-426. DOI: 10.1016/j.berh.2018.08.003.
[5]	Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis[J]. Arthritis Rheum, 1984, 27(4): 361-368. DOI: 10.1002/art.1780270401.
[6]	Smolen JS, Braun J, Dougados M, et al. Extended report: treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force[J]. Ann Rheum Dis, 2014, 73(1): 6. DOI: 10.1136/annrheumdis-2013-203419.
[7]	Braun J, Van dHB, Irene E, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial[J]. Arthritis Rheum, 2011, 63(6): 1543. DOI: 10.1002/art.30223.
[8]	Kádár G, Balázs E, Soós B, et al. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases[J]. Clin Rheumatol, 2014, 33(3): 329-333. DOI: 10.1007/s10067-014-2508-3.
[9]	Osman MS, Maksymowych WP. An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis[J]. Expert Rev Clin Immunol, 2017, 13(2): 125-131. DOI: 10.1080/1744666X.2016.1218761.
[10]	Tong Q, Cai Q, De MT, et al. Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis[J]. Plos One, 2015, 10(3): e0119897. DOI: 10.1371/journal.pone.0119897.
[11]	Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review[J]. BioDrugs, 2017, 31(4): 299-316. DOI: 10.1007/s40259-017-0231-8.
[12]	Steiman AJ, Pope JE, Thiessen-Philbrook H, et al. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials[J]. Rheumatol Int, 2013, 33(5): 1105-1120. DOI: 10.1007/s00296-012-2619-6.
[13]	Yu HC, Lu MC, Huang KY, et al. Sulfasalazine treatment suppresses the formation of HLA-B27 heavy chain homodimer in patients with ankylosing spondylitis[J]. Int J Mol Sci, 2015, 17(1): 46. DOI: 10.3390/ijms17010046.
[14]	Relas H, Kautiainen H, Puolakka K, et al. Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study[J]. Clin Rheumatol, 2014, 33(8): 1135-1138. DOI: 10.1007/s10067-014-2700-5.
[15]	O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheum, 2002, 46(5): 1164. DOI: 10.1002/art.10228.

依那西普和传统合成改变病情抗风湿药序贯治疗轻中度强直性脊柱炎的中期疗效随访研究

Sequential application of etanercept and csDMARDs in treating ankylosing spondylitis: A prospectively mid-term follow-up study

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	江剑宏, 段仁鹏, 李晓锋. 国人胆道三维重建解剖变异应用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 1-4.
[2]	郭红志, 王瑜, 张加琪, 梁海彬, 马梓玮, 冯伟, 吴忧, 司子燚. 血管铸型结合CT三维模型评估先兆子痫胎盘血管结构[J]. 中国临床解剖学杂志, 2024, 42(1): 5-10.
[3]	李佳伟, 张静, 李灿然, 兰文杰, 籍庆余, 郭志勇, 张云凤, 刘启, 陈清威, 李筱贺. 蒙古族人群股骨近端解剖参数X线测量[J]. 中国临床解剖学杂志, 2024, 42(1): 11-16.
[4]	李琨, 张燕, 郭冉, 郝咪咪, 吴轩宇, 徐艺芳, 王超群, 马文童, 张灵淇, 杨宏宇, 李志军, 张少杰, 王星. 儿童及青少年枕颈角与后枕颈角数字化测量及其临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 17-20.
[5]	李文, 杨思艺, 黄蕾, 卿霁雯, 蒋松涛, 张磊. 基于MRI探讨Lisfranc韧带的形态学特点及临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 21-25.
[6]	李凡凡, 徐阳, 王晓旭. 紫草素调节Nrf2/HO-1信号通路对实验性大鼠肉芽肿性小叶性乳腺炎的治疗作用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 26-32.
[7]	王兴航, 丁佳媛, 李放, 包翠芬, 阎丽菁. 人参皂苷Rg1通过抑制NLRP3炎症小体途径减轻氧糖剥夺/复供后小胶质细胞炎症反应[J]. 中国临床解剖学杂志, 2024, 42(1): 33-41.
[8]	程莹莹, 武建军, 蔡海燕, 焦旭文, 马江波, 丁银秀. 体外炎性诱导星形胶质细胞激活及功能分析[J]. 中国临床解剖学杂志, 2024, 42(1): 42-46.
[9]	祁志, 杨力, 贾秋叶, 陈浩伦, 段兆达, 吴春云. 依达拉奉经MAPKs通路对脂多糖激活的小胶质细胞Sirt3表达调控[J]. 中国临床解剖学杂志, 2024, 42(1): 47-53.
[10]	张晶晶, 王洪新. 黄芩苷通过PDGF/P38 MAPK信号通路对肺动脉高压大鼠的保护作用[J]. 中国临床解剖学杂志, 2024, 42(1): 54-58.
[11]	乐钦, 陈荣丽, 熊婧熙, 王婷怡, 蔡志恒, 易秋实, 曾心怡. 白芨多糖对大鼠跨区皮瓣choke区的影响[J]. 中国临床解剖学杂志, 2024, 42(1): 59-64.
[12]	李笑予, 张磊, 付磊, 李东波, 汪国友. 三步接骨法治疗Sanders Ⅱ型跟骨骨折的有限元研究[J]. 中国临床解剖学杂志, 2024, 42(1): 65-70.
[13]	吴研飞, 马剑雄, 卢斌, 王颖, 柏豪豪, 靳洪震, 马信龙. CT后处理技术重建CT值与终板抗压强度的相关性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 71-76.
[14]	庄万强, 唐毅, 骆勇刚, 张辉. 关节镜联合胫骨高位截骨术对髌骨位置及髌股关节功能影响的早中期回顾性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 77-82.
[15]	罗鹰, 窦伟誉, 吴小杭, 陈璟昆, 彭昌贵, 潘剑英 . 微创海马钢板内固定治疗跟骨骨折并发症的影响因素[J]. 中国临床解剖学杂志, 2024, 42(1): 83-88.